Mortimer Ian's Form 4 filing
Xenon Pharmaceuticals Inc. (XENE) · filed Dec 9, 2025
- Accession no.
- 0001193125-25-313147
- Filed
- Dec 9, 2025
- Trade date
- Dec 5-8, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $1.14M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Mortimer IanCIK 0001619961 | Director, Officer (PRESIDENT & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 5, 2025 | Common Shares | SSaleDisposed | −14,375 | $45.03 | −$647,306.25 | 16,830 | Direct | |
| Dec 8, 2025 | Common Shares | SSaleDisposed | −8,820 | $45.59 | −$402,103.8 | 8,010 | Direct | |
| Dec 8, 2025 | Common Shares | SSaleDisposed | −2,010 | $46.32 | −$93,103.2 | 6,000 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.